The Diagnostic Process: What the Tests Tell You
At a Glance
Doctors distinguish primary from secondary Raynaud disease using symptom history, physical examination, nailfold capillaroscopy, and blood tests such as ANA and disease-specific antibodies. Doppler ultrasound or an Allen test is used when a larger-artery blockage is suspected.
The central goal of a medical evaluation for Raynaud phenomenon is to determine if your symptoms are primary (an isolated, functional issue) or secondary (a sign of an underlying autoimmune or vascular condition, or a result of an exposure or medication) [1]. While the symptoms of cold-triggered color changes can feel the same in both types, the diagnostic workup looks beneath the surface to examine the structure of your blood vessels and the activity of your immune system [2].
The Role of Nailfold Capillaroscopy
One of the most important tools in this process is nailfold capillaroscopy. This is a non-invasive test where a doctor applies a drop of oil to the skin at the base of your fingernail and uses a specialized microscope to look at your capillaries (the smallest blood vessels in the body) [3]. Because the skin is thinnest at the nailfold, doctors can see these vessels in detail [3].
- Normal Pattern: In a healthy person or someone with primary Raynaud’s, the capillaries look like an orderly row of neat, parallel “hairpin” loops [4].
- Suggestive Abnormal Patterns: In some forms of secondary Raynaud’s—particularly when associated with conditions like systemic sclerosis—the vessels show clear signs of structural damage [5]:
- Giant Capillaries: These are significantly enlarged loops, often one of the earliest visible changes [5][4].
- Microhemorrhages: Tiny spots of bleeding where a vessel has leaked or burst [5].
- Avascular Areas: This refers to fields under the microscope where capillaries are no longer visible, meaning there are fewer visible vessels in that specific area (it does not mean the skin has lost all blood supply or is dying) [5].
- Architectural Distortion: The neat rows become disorganized, with vessels twisting or branching in unusual ways [5][4].
It is important to remember that these capillaroscopic patterns are suggestive rather than diagnostic, and must be interpreted alongside your clinical examination.
Autoantibody Testing and Risk Prediction
Blood tests for autoantibodies (proteins produced by the immune system that mistakenly target the body’s own tissues) help doctors estimate the risk of an underlying condition [6].
- ANA (Antinuclear Antibody): This is a broad screening test. A negative ANA is a reassuring sign that lowers the likelihood of certain connective-tissue diseases. However, a negative ANA does not definitively rule out all secondary causes, and any risk percentage depends heavily on your specific symptoms, examination, and capillaroscopy [7].
- Disease-Specific Antibodies: If the ANA is positive, doctors look for specific markers that act as “red flags” for certain conditions [6]:
- Anticentromere: Often associated with a more gradual form of systemic sclerosis [8].
- Scl-70 (Anti-topoisomerase I): Associated with a risk of systemic sclerosis that may involve the skin and internal organs [9].
- Anti-RNA Polymerase III: Linked to a risk of more rapid skin changes or kidney involvement if systemic sclerosis develops [10].
The presence of these antibodies, combined with physical signs like puffy fingers, significantly increases the likelihood that Raynaud’s is secondary [7]. Still, many people with positive antibodies remain stable for years without ever progressing to a systemic disease.
Targeted Vascular Assessment
While Raynaud’s involves temporary spasms, doctors sometimes must ensure that your blood vessels aren’t permanently blocked (occlusion) by other factors [1]. These tests are not part of a routine autoimmune workup for everyone, but are selected when you have asymmetric symptoms, absent pulses, or concerns about arterial blockages:
- Doppler Ultrasound: This test uses sound waves to measure blood flow through your larger arteries [11]. It can help evaluate conditions like atherosclerosis (hardening of the arteries).
- Allen Test: A simple bedside test where the doctor compresses the arteries at your wrist to see how quickly blood returns to your hand when they are released [11].
Elements of a Clinical Evaluation
A thorough diagnostic evaluation typically relies on [6][1]:
- Detailed History: Focusing on age of onset, symmetry of symptoms, occupational exposures, medications, and triggers.
- Physical Exam: Looking for fingertip sores (ulcers), skin thickening, or “puffy” hands.
- Capillaroscopy: To check the structural health of the smallest vessels, if available.
- Laboratory Panels: Including ANA and targeted antibodies.
- Vascular Testing: Only when the history or exam suggests an underlying arterial blockage or structural issue.
By combining these findings, your care team determines whether your symptoms are primary Raynaud’s or a sign that your vascular system requires closer monitoring.
Common questions in this guide
How do doctors decide whether Raynaud is primary or secondary?
What can nailfold capillaroscopy reveal about my Raynaud symptoms?
Does a negative ANA rule out a secondary cause of Raynaud?
What do Scl-70 and anticentromere antibody results mean?
When would I need a Doppler ultrasound or Allen test?
Does a positive antibody test mean I will develop an autoimmune disease?
One line in your results can change your plan.
Whether Doppler ultrasound or an Allen test is selected depends on asymmetric symptoms, absent pulses, or arterial blockage concerns. We check your results against the latest research to help you prepare for what’s next.
Get notified when new evidence is published on Raynaud disease.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (11)
- 1
Raynaud's Phenomenon: A Vascular Acrosyndrome That Requires Long-Term Care.
Klein-Weigel P, Sander O, Reinhold S, et al.
Deutsches Arzteblatt international 2021; (118(Forthcoming)).
PMID: 33632387 - 2
Raynaud's Phenomenon: A Current Update on Pathogenesis, Diagnostic Workup, and Treatment.
Ture HY, Lee NY, Kim NR, Nam EJ
Vascular specialist international 2024; (40()):26 doi:10.5758/vsi.240047.
PMID: 39040029 - 3
[Paroxysmal vascular acrosyndromes: Practical approach to diagnosis and management].
Senet P
La Revue de medecine interne 2022; (43(10)):596-602 doi:10.1016/j.revmed.2022.03.338.
PMID: 35835622 - 4
Nailfold capillaroscopy in systemic diseases: short overview for internal medicine.
Dima A, Berza I, Popescu DN, Parvu MI
Romanian journal of internal medicine = Revue roumaine de medecine interne 2021; (59(3)):201-217 doi:10.2478/rjim-2021-0007.
PMID: 33600677 - 5
Position article and guidelines 2018 recommendations of the Brazilian Society of Rheumatology for the indication, interpretation and performance of nailfold capillaroscopy.
Kayser C, Bredemeier M, Caleiro MT, et al.
Advances in rheumatology (London, England) 2019; (59(1)):5 doi:10.1186/s42358-018-0046-4.
PMID: 30670098 - 6
Recent advances in the workup and management of Raynaud phenomenon.
Lis-Święty A
Polish archives of internal medicine 2019; (129(11)):798-808 doi:10.20452/pamw.15008.
PMID: 31577265 - 7
Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS).
Bellando-Randone S, Del Galdo F, Lepri G, et al.
The Lancet. Rheumatology 2021; (3(12)):e834-e843 doi:10.1016/S2665-9913(21)00244-7.
PMID: 38287630 - 8
Anticentromere Antibody Levels and Isotypes and the Development of Systemic Sclerosis.
van Leeuwen NM, Boonstra M, Bakker JA, et al.
Arthritis & rheumatology (Hoboken, N.J.) 2021; (73(12)):2338-2347 doi:10.1002/art.41814.
PMID: 34042326 - 9
Progression from suspected to definite systemic sclerosis and the role of anti-topoisomerase I antibodies.
Liem SIE, Neppelenbroek S, Fehres CM, et al.
RMD open 2023; (9(1)) doi:10.1136/rmdopen-2022-002827.
PMID: 36746531 - 10
Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study.
Jaeger VK, Wirz EG, Allanore Y, et al.
PloS one 2016; (11(10)):e0163894 doi:10.1371/journal.pone.0163894.
PMID: 27706206 - 11
Vascular trauma of the hand - a systematic review.
Wahl U, Kaden I, Köhler A, Hirsch T
VASA. Zeitschrift fur Gefasskrankheiten 2019; (48(3)):205-215 doi:10.1024/0301-1526/a000743.
PMID: 30322339
This page explains Raynaud disease testing for informational purposes only and does not constitute medical advice. A clinician should interpret your examination, capillaroscopy, blood tests, and vascular results in context.